BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Artemisinin Combination Therapy Market – Global Forecast 2026-2032” has been added to ResearchAndMarkets.com’s offering. The Artemisinin Combination Therapy (ACT) market exemplifies dynamic growth and promising potential in the treatment of malaria. Expected to increase from USD 386.40 million in 2025 to USD 608.26 million by 2032, supported by a steady CAGR of 6.69%, … [Read more…]
ASD Insight Test is a Critical Step in Redefining Autism as a Biologically Measurable Condition IRVINE, Calif.–(BUSINESS WIRE)–#AutismAwareness—NeuroQure, a pioneering leader in neurological diagnostics, announces the launch of ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. Representing a critical step in redefining autism as a biologically measurable condition, ASD … [Read more…]
Rerouting Minds is designed to increase understanding of pharmaceutical lysergide (LSD) and the role of rigorous psychedelic research in addressing unmet needs in severe mental health disorders NEW YORK–(BUSINESS WIRE)–Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric … [Read more…]
Following discussions with the U.S. FDA, the Agency recommended that the Company submit additional information for its evaluation of this information to potentially support a resubmission of the sBLA for BCG-unresponsive papillary NMIBC The additional information does not include the initiation or design of any new clinical trials, and the Company will provide the requested … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “D-Lysine Monohydrochloride (CAS 7274-88-6) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering. This report on D-Lysine monohydrochloride provides comprehensive insights, including general information, synonyms, chemical composition, safety, hazards, handling, storage, and toxicological and ecological details, along with transport information. This in-depth … [Read more…]
Clinic may provide effective ketamine therapy for those who haven’t responded to medication NOCATEE, Fla.–(BUSINESS WIRE)–Serenity Mental Health Centers, a leader in psychiatric care and one of the fastest growing mental health providers in the nation, today announced the expansion of its ketamine treatment in Nocatee. Serenity’s board-certified psychiatrists and psychiatric mental health nurse practitioners … [Read more…]
WASHINGTON–(BUSINESS WIRE)–#CommunityCare–Wellpoint DC (formerly Amerigroup District of Columbia) is starting the new year by announcing it has been awarded NCQA Health Outcomes Accreditation and NCQA Community-Focused Care Accreditation—formerly Health Equity Accreditation and Health Equity Accreditation Plus—for its Medicaid health plan. Combined with its NCQA Health Plan Accreditation earned in October 2025, this distinction makes Wellpoint … [Read more…]
LONDON & CAIRO–(BUSINESS WIRE)–Alta Semper, a London-based private equity firm focused on healthcare and consumer investments across growth markets, today announced that it has signed definitive agreements to acquire a majority stake in Nature’s Rule, a leading sports nutrition and dietary supplements company headquartered in the UAE, with an established manufacturing presence in Egypt. The … [Read more…]
Record iCRO bookings in 2025; order backlog at an all-time high of €76.6 million despite negative forex impact of € (6.5) million 2025 revenue of €23.5 million, up 2.6% vs 2024 despite negative forex impact of € (0.8) million FDA decision for eyonis® LCS expected in the coming weeks; CE marking anticipated in Q2 2026 … [Read more…]
